

20 September 2019



Following a Melbourne visit by MedAchievers (Indian joint venture partner), Respiri Limited (ASX:RSH) is pleased to announce an update on a multi-centre pre-market exercise. The pilot use of wheezo® will lead to clinical credibility and replicates the protocol from wheezo's first Australian based trial.

The productive visit by Dr Harsha Vardhan, the founder of MedAchievers, included a site visit to the SRX manufacturing facility in Dandenong, planning for large demand requirements in India and the process of delivering the product.

The continued planning for large scale orders and clinical studies are significant steps forward following our Indian market introduction at the Delhi MedAchievers hosted MedParliament in late July. This event was recently covered by CNBC and Forbes India.

<https://www.youtube.com/watch?v=TrcDpMvQiGs>

<http://www.forbesindia.com/showstory.php?flag=p&id=55217>

The pre-market use of wheezo involves three large healthcare institutions with over 4,500 beds combined, covering North and South India. Commencement will be the first week of October with 50 wheezos facilitating clinical acceptance and treatment protocols in the lead up to complete roll out of the product to patients.

CEO Mario Gattino stated, "Respiri is pleased with the continued progress and integration with MedAchievers since the May 2019 commencement of the relationship. The clinical entry into the Indian market is a significant milestone for the company."

Dr Harsha Vardhan from MedAchievers said, "India and Australia need to share the most effective possible ways to advance clinical management. With Respiri, MedAchievers firmly believes that we will provide an avenue to improved asthma and COPD care. Our studies and market entry activities using the Respiri technology and MedAchievers clinical strength are forming a very important partnership which will improve patient lives."

Respiri's joint venture in India is an integral part of the Company's overall strategy. In addition to building a market in India, the Company is committed to its three core short term objectives, namely:

1. Obtain product certification for device sales in the Australian and European/UK markets followed closely by the US market.
2. Develop steady state manufacturing processes with SRX Global, the company's current manufacturing partner in Dandenong, Victoria.
3. Undertake a breadth of clinical trials to provide confidence in the performance of the device, and the app, in a number of clinical situations.

--END--

Contact:

Mario Gattino
CEO & Director
+61 3 9653 9160

About Respi Limited

Respi's mission is to help improve quality of life for millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. The Company offers sensors, mobile apps and analytics to support respiratory health management. Its world first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. Respi's innovative platform provides personalised feedback and education based on the user's data and enables the sharing of that data with caregivers and health care providers. Respi Limited's operations are based in Melbourne, Australia.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respi's current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respi, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respi cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respi only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respi will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.